On Friday July 20, 2012, America’s Food and Drug Administration (FDA) has approved a new type of drug to treat women with advanced breast cancer marketed by Novartis Pharmaceuticals Corporation. The new drug is known as Afinitor. Previously, some of the ingredients of the drug had received approval to treat various tumors including pancreas, kidney and brain. According to FDA, the drug combination of Afinitor is being used to treat postmenopausal patients.
Before getting a stamp of approval from FDA, the East Hanover, New Jersey-based company conducted a study of 724 patients. Samples were divided into two groups. The first group received drug combination of Afinitor and the breast cancer drug Aromasin. The second group received a combo of a placebo pill and Aromasin. The results showed that women who received combo of two-drug, Afinitor and Aromasin, increased their life span for about 4.6 months and the breast cancer disease has stopped to progress.
(Image: Afinitor 5mg tablet)